- Home
- VCTR vs MIRM Comparison
VCTR vs MIRM Comparison
Compare VCTR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VCTR | MIRM |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 7.2B |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VCTR | MIRM |
|---|---|---|
| Price | $124.78 | $93.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $129.33 | ★ $154.00 |
| AVG Volume (30 Days) | 547.9K | ★ 571.5K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 4.11 | N/A |
| Revenue | ★ $413,412,000.00 | $19,138,000.00 |
| Revenue This Year | $25.02 | $37.65 |
| Revenue Next Year | $30.91 | $21.04 |
| P/E Ratio | $30.40 | ★ N/A |
| Revenue Growth | ★ 0.92 | N/A |
| 52 Week Low | $60.74 | $63.23 |
| 52 Week High | $129.31 | $130.00 |
Technical Indicators
Market Signals| Indicator | VCTR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 59.57 |
| Support Level | $110.34 | $87.38 |
| Resistance Level | N/A | $98.34 |
| Average True Range (ATR) | 4.71 | 4.28 |
| MACD | 1.30 | 0.96 |
| Stochastic Oscillator | 78.35 | 68.65 |
Price Performance
Historical ComparisonAbout VCTR Victory Capital Holdings Inc.
Victory Capital Holdings Inc is a diversified investment management firm. The company provides specialized investment strategies to institutions, intermediaries, retirement platforms and individual investors. Its offerings include actively and passively managed mutual funds, rules-based and active exchange traded funds (ETFs), institutional separate accounts, variable insurance products (VIPs), alternative investments, private closed end funds, and a 529 Education Savings Plan. The company operates in one operating and reportable segment that provides investment management services and products to institutional, intermediary, retirement platforms and individual investors. The majority of the company's revenue consists of Investment management fees.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.